OBJECTIVE—The purpose of this study was to determine longitudinal predictors of impaired mobility and physical disability in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—We studied patients with type 2 diabetes who participated in a prospective, community-based study. A wide range of baseline variables were examined to determine whether they predicted future difficulties with 1) mobility and 2) basic activities of daily living (ADLs) in patients free of ADLs difficulty at baseline. To study mobility impairment, subjects with baseline mobility problems were also excluded.

RESULTS—After an average 4.6 ± 2.3 and 4.8 ± 2.3 years of follow-up in 818 and 934 patients, respectively, 28.5% of subjects had developed new mobility impairment and 18.1% had developed new ADL disability. In Cox proportional hazards models, the risk of mobility impairment was significantly increased by older age (6%/year), peripheral neuropathy (40% increase), stroke history (123%), insulin treatment (117%), albuminuria, and arthritis (82%); taking exercise and being married lowered the risk (by 39 and 32%, respectively). The risk of new ADL disability was increased by baseline mobility problems (222% increase), stroke (92%), claudication (67%), and depression (41%) and was also influenced by age, smoking, lack of exercise, nonfluency in English, and indigenous Australian ethnicity.

CONCLUSIONS—Both mobility impairment and ADL disability in type 2 diabetes have multiple causes that are due to diabetes complications and common comorbidities. The specific causes of each functional problem are largely distinct, and different approaches may be required to prevent their onset or progression.

Both cross-sectional (13) and longitudinal studies (46) have demonstrated that type 2 diabetes is a risk factor for physical disability, particularly in older people. Because the prevalence of diabetes is increasing, especially in older age-groups (7) and in view of the greater health burden of disabled diabetic patients (8,9), an understanding of the factors contributing to disability in individuals with diabetes has important clinical implications. These include the use of preventive strategies (10).

The disablement process in older people represents a complex dynamic interaction among individual disease states (including microvascular and macrovascular complications in diabetes), impairments, and functional limitations and is moderated by a range of social, economic, and behavioral influences (1113). Consequently, it is not surprising that multiple factors have been implicated in the development of disability in type 2 diabetic patients. Cross-sectional associations have included age (13), sex (1,3), obesity (13), insulin treatment (3), peripheral neuropathy (3), coronary heart disease (CHD) (1,3), stroke (1), peripheral arterial disease (1,2), vision loss (1), depression (2,3), and arthritis (1,2). One longitudinal study of incident disability in older diabetic women found associations with baseline functional difficulty, older age, obesity, physical inactivity, CHD, arthritis, and vision loss (5). The authors of another study of mobility problems in frail older diabetic women reported that a decline in mobility was not fully explained by baseline diabetes complications and that chronic hyperglycemia was important (6). Because both studies had incomplete datasets on relevant diabetes-related variables, including diabetes diagnosis (5), glycemic control, and complications (5,6), only limited conclusions can be drawn.

The disablement process is often progressive, owing to an accumulation or worsening of impairments (11,12). In particular, an impairment in mobility predicts future physical disability as measured by difficulty with activities of daily living (ADLs) (14,15). Based on this observation, we hypothesized that the profile of risk factors for mobility impairment differs from that for ADL disability in diabetes and that studying the disablement process at different stages could reduce the complexity found in previous studies and increase our understanding of how diabetes leads to disability. We therefore analyzed prospective data from a large well-characterized, community-based cohort of patients with type 2 diabetes to assess the risk factors for future impairments in mobility and the development of difficulties with basic ADLs.

We studied patients with type 2 diabetes recruited to the Fremantle Diabetes Study (FDS). The FDS was a prospective observational study of a representative sample of patients from a postcode-defined community of 120,097 people in Fremantle, Western Australia. The FDS protocol was approved by the human rights committee of Fremantle Hospital, and all subjects gave informed consent before participation. All people with diabetes living in the region were eligible to participate. Identification and recruitment methods, sample characteristics including classification of diabetes, and details of nonrecruited patients have been described elsewhere (1618).

We identified 2,258 individuals with diabetes between 1993 and 1996 and recruited 1,426 (63%) to the FDS. Based on contemporaneous national data, this number was consistent with the proportion expected to have diabetes. Type 2 diabetes was defined clinically, after excluding secondary diabetes, as that 1) treated with diet and/or oral hypoglycemic agents irrespective of age at diagnosis, 2) in patients aged ≥60 years at diagnosis whatever the treatment history, and 3) diagnosed between 40 and 60 years of age, treated with insulin at study entry but not at diagnosis, and associated with a BMI >30 kg/m2. The FDS cohort included 1,294 (91%) type 2 diabetic subjects (mean age 64.1 ± 11.3 years, range 14.9–96.9).

The present study excluded subjects who did not return for follow-up assessment (259 subjects) and those with baseline disability. Two overlapping subgroups were studied: 1) 818 subjects who were free of mobility impairment and independent in ADLs at baseline (group 1) and 2) 934 subjects who were free of ADL problems at baseline (i.e., not excluding impaired mobility) (group 2). All subjects had at least partial follow-up, and attrition from the study by closeout (1 November 2001) was due to death (170 subjects from group 1 and 202 from group 2), moving from the study area (73 and 82 subjects, respectively), withdrawal (190 and 220 subjects, respectively), and unknown reasons (17 and 19, respectively).

Clinical assessment

At each patient’s first and subsequent annual FDS visits, a comprehensive history was taken and a physical examination was performed. Detailed demographic and socioeconomic data were recorded, as was information relating to diabetes and its complications and all other comorbid conditions. Patients reported whether they had participated in physical exercise in the 2 weeks before the assessment. Each patient provided fasting blood and urine samples for automated biochemical analyses including the urinary albumin-to-creatinine ratio (17).

Peripheral sensory neuropathy was defined using the clinical portion of the Michigan Neuropathy Screening Instrument (19). Retinopathy was defined if any grade of retinopathy, including maculopathy, was detected by direct and/or indirect ophthalmoscopy in one or both eyes and/or more detailed data in patients assessed for photocoagulation. Visual acuity was assessed using Snellen charts and classified as normal (≥6/12 in the best corrected eye), impaired (<6/12 best corrected with pinhole or glasses but ≥6/120 in both eyes), or blind (in one or both eyes <6/120).

Self-reported stroke and transient ischemic attack were amalgamated with prior hospitalizations to define baseline cerebrovascular disease (CVD) status (20). Patients were classified as having CHD if there was a self-reported/hospital history of myocardial infarction, angina, coronary artery bypass grafting, angioplasty, and/or definite myocardial infarction on Minnesota coding of a resting 12-lead electrocardiogram (codes 1-1 and 1-2) (18). The ankle-to-brachial index was obtained by using brachial and ankle (with Doppler detection) systolic blood pressures and peripheral vascular disease was defined as ankle-to-brachial index ≤0.90.

Assessment of depression, mobility, and ADLs

All subjects completed the General Health Status (GHS) questionnaire (21), which addresses the five health domains of physical activity, self-care, pain, mental health, and autonomy. The assessment of depression was based on self-reporting of mood symptoms contained in the GHS. Subjects rated the presence and extent of feeling sad/depressed, anxious/worried, uncertain about the future, anger/resentment, guilt, loneliness, loss of self-confidence, difficulty sleeping, lack of energy, and inability to concentrate over the previous 2 weeks. A 10-cm visual-analog scale from “No distress at all” to “Extreme distress” was used for each variable.

Because this methodology has not previously been validated for the assessment of depression, we recruited a separate convenience sample of 51 patients (mean age 67.7 ± 6.0 years; 60.8% males) with type 2 diabetes drawn from other research studies. A trained researcher rated the subjects for the presence of DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) depression syndromes using the Mini International Neuropsychiatric Interview that has been validated for making the major Axis I DSM-IV depression diagnoses (22). We decided a priori that GHS depression symptoms were present if a rating of ≥5 cm was chosen on the visual-analog scale and then determined whether the presence of ≥1, ≥2 or ≥3 GHS symptoms predicted DSM-IV depression. Twelve of the patients had clinical depression (six major depression, three minor depression, and three dysthymia). The presence of ≥2 GHS symptoms proved to be the best predictor of clinical depression (sensitivity 83.3% [95% CI 50.9–97.1], specificity 94.8% [81.4–99.1], positive predictive value 83.3% (50.9–97.1), and negative predictive value 94.8% [81.4–99.1]) and was used to identify baseline depression in the present FDS patients.

The GHS assesses four ADLs and mobility separately. Subjects were asked: “Do you have difficulty with any of the activities listed below? If you do, do you also need help from someone else to do them?” They self-rated their ability on the following: “Washing yourself,” “Dressing yourself,” “Eating and drinking,” and “Using the toilet,” by choosing from three degrees of difficulty: 1, no difficulty at all; 2, some difficulty but cope on my own; or 3, such difficulty that I need someone’s help. Because subjects who report difficulty but who can carry out ADLs independently have an increased risk for future ADL dependency (23), we dichotomized the data into no difficulty or any difficulty with ADLs to facilitate analysis.

The subjects selected one of six statements that best described their mobility: 1) I can move around indoors and outdoors on my own easily with no aids or help; 2) I can move around indoors and outdoors on my own with a little difficulty but with no aids or help; 3) I can get about indoors and outdoors on my own but I have to use a walking aid (e.g., stick, frame, crutch, wheelchair, etc.); 4) I can move around the house without anyone’s help, but I need someone’s help to get outdoors; 5) I spend nearly all my time confined to a chair (other than wheelchair); or 6) I spend nearly all my time in bed. We dichotomized the data into normal mobility compared with any difficulty with mobility.

Statistical analysis

The computer package SPSS for Windows (version 11.5; SPSS, Chicago, IL) was used. Data are presented as proportions, means ± SD, or geometric mean ± SD (range), or for variables that did not conform to a normal or ln-normal distribution, median (interquartile range). The Student’s t test was used for comparison of two means, Fisher’s exact test for two proportions, and the χ2 test for multiple proportions. Two-group nonparametric comparisons were performed with the Mann-Whitney U test.

Cox proportional hazards modeling (forward conditional variable entry and removal with P < 0.05 and > 0.10, respectively) was used to determine independent predictors of future mobility problems. This technique permits censoring of patients lost to follow-up and uses data on all baseline patients who attend at least one review. All clinically plausible univariate variables with P < 0.20 were considered for entry into the model. Similar Cox modeling was used to determine whether baseline mobility status was an independent predictor of future difficulties with ADLs after adjustment for other explanatory variables. Survival curves defined by baseline mobility status were constructed with the use of Kaplan-Meier estimates and compared with the log-rank test. The validity of the proportional hazards assumption was assessed from log(−log[survival]) curves, plots of residual β values versus time, and examination of time-dependent covariates.

Predictors of mobility impairment

The 818 group 1 patients had a mean ± SD age of 62.5 ± 10.2 years, a median duration of diabetes of 3.0 years (interquartile range 0.8–7.8), and 50.0% were males. After an average of 4.6 ± 2.3 years follow-up, 28.5% had developed problems with mobility (77.7% reported having a little difficulty, 16.7% moved around with an aide, 4.3% needed help of another to go outdoors, and 1.3% reported being bed/chair fast). In univariate analyses, a large number of baseline variables were significantly associated with the subsequent development of mobility impairment (Table 1). Nonsignificant variables not displayed in Table 1 included fasting glucose, HbA1c (A1C), diastolic blood pressure, cholesterol, triglycerides, lipid-lowering therapy, lower-limb amputation, mental illness, and taking antidepressants (all P > 0.20).

In a time-dependent Cox proportional hazards model including ln(time) and mobility status, the interaction between these variables was significant (P < 0.001). This indicated that the proportional hazards assumption may be invalid. However the log(−log[survival]) curves were parallel, and inspection of the residual β values versus time plots for all significant covariates revealed no outliers. Therefore, we concluded that the nonproportionality made no difference to the interpretation of the data (24). In the Cox model, older age, CVD, treatment with insulin, microalbuminuria, peripheral neuropathy, arthritis, current smoking, unmarried status, and not taking exercise remained independently associated with the development of mobility impairment (Table 2). When insulin treatment was removed from the Cox model, retinopathy and nonfluency in English became significant.

Predictors of ADL disability

The 934 group 2 patients had a mean ± SD age of 63.5 ± 10.4 years, a median duration of diabetes of 3.0 years (interquartile range 0.8–8.0), and 49.7% were men. After an average of 4.8 ± 2.3 years follow-up, 169 (18.1%) reported having any difficulty with any ADL (152 reported having some difficulty with at least one ADL and 17 reported requiring another’s help for at least one ADL). A large number of baseline variables correlated significantly in univariate analyses with the development of ADL disability (Table 1). Nonsignificant variables not displayed in the table included fasting glucose, A1C, diastolic blood pressure, cholesterol, triglycerides, lipid-lowering therapy, lower-limb amputation, mental illness, and taking antipsychotic medications (all P > 0.20).

In Cox proportional hazards modeling, age, CVD, not taking exercise, smoking status, claudication, mobility problems, depression, nonfluency in English, and indigenous Australian ethnicity independently predicted the development of ADL disability (Table 2). The cumulative survival curves for patients remaining free of ADL disability in patients with and without baseline mobility problems are shown in Fig. 1 (P < 0.0001, log-rank test).

In the present prospective community-based study of patients with type 2 diabetes, almost one-third of the subjects with normal mobility at baseline developed some degree of mobility impairment after an average of 4.6 years, and close to one-fifth developed new difficulties with basic ADLs within the same time frame. The majority of subjects developed relatively minor physical deficits. For example, nearly 80% of those reporting mobility problems did not require a walking aide, and few subjects became fully dependent on another person for assistance with ADLs. Nevertheless, even minor impairments in mobility predicted future functional decline in the general population (14), and consistent with this observation, those of our subjects who reported difficulty with mobility at baseline had more than three times the risk of subsequently developing ADL disability.

As in previous reports (5,6), the development of new mobility impairment and ADL disability was multifactorial and largely explained by diabetes complications, common comorbid conditions, cardiovascular risk factors, and several social factors. However, although there were similarities in the etiological factors involved in the two disabling processes, there were also differences that may be useful in understanding disablement in diabetes. Patients who developed mobility impairment were more likely to have peripheral neuropathy and a history of stroke and arthritis at baseline, conditions known to affect lower-limb function and to cause gait disorders (12,25,26). Why baseline insulin therapy and microalbuminuria predicted mobility impairment is less clear, but removal of insulin treatment from the Cox model caused retinopathy to enter as an additional predictor, suggesting that microangiopathy may directly or indirectly affect lower-limb function. ADL disability also had multiple causes, with the strongest predictive variable being baseline mobility impairment. The other disease-related risk factors for ADL disability, namely stroke, peripheral vascular disease, and depression, are known causes of disability in the general population (12,27) and all, including depression, occur with an increased frequency in type 2 diabetes (28). Presumably one or more such conditions progressed to cause further functional limitation and ultimately disability (29).

Our definition of ADL disability did not include mobility assessment unlike many ADL assessment tools. This important distinction may explain why other studies have found common determinants (12) when we found different etiological factors for mobility impairment and ADL disability. The stepwise analytical approach we used relies on statistical significance irrespective of the strength of associations in two unequal groups, which might have influenced the results. Nevertheless, the model predictors had sizeable effects and the group sizes were large.

The increased risk of mobility impairment and disability in our patients was explained by the complications of diabetes in combination with several common age-related disorders, but we found no role for hyperglycemia or CHD. These findings are inconsistent with other longitudinal studies (5,6), but there are important differences in study design and the numbers of assessed variables. We considered predictors of disability within a diabetic cohort rather than comparing diabetic with nondiabetic subjects (5,6). In addition, the two previous studies had limited data on diabetes diagnosis, glycemic control, and micro- and macrovascular complications (5,6). CHD has been an important factor in other studies of disability (12). Age adjustment alone attenuated, at least in part, the univariate association seen in the present study (data not shown). Our method of assessing CHD and CVD was rigorous; patient self-reports being supplemented with hospital records and electrocardiographic data for confirmation and to diagnose silent ischemia (18). The instrument we used may be relevant because the GHS relies on self-reports, and we had no objective measures of physical function. Self-reported data can also be compromised by cognitive difficulties, although we used attendant relatives as additional sources of information where necessary.

Diabetic peripheral neuropathy affects mobility through altered balance and posture (25,26), but the nature of an association between mobility and the other microvascular complications is less clear. Age-related muscle loss is a powerful risk factor for disability (30), especially in patients with renal disease (31). It is possible that progression of neuropathy and nephropathy in our patients contributed to a reduction in muscle mass with a consequent impact on mobility. The contribution of retinopathy to this process in the absence of differences in visual acuity is difficult to explain and may reflect the strong intercorrelation between microvascular complications.

Our finding that lifestyle and social and cultural factors were important determinants of the risk of mobility impairment and ADL disability indicates potential areas for disability prevention in diabetic populations, especially in regard to smoking and exercise. Two groups had a heightened risk for becoming disabled, specifically migrants with limited fluency in English and indigenous Australians. Although the number of indigenous Australians in this study was small and the confidence intervals for the estimates wide, these data are consistent with studies demonstrating a high disability burden in indigenous Australians (32). The majority of people who were nonfluent in English in our study are elderly migrants of Southern European origin, principally Italian and Portuguese. The literature on disability has attributed racial differences to economic factors (12). We have previously reported that non–English-speaking diabetic migrants in Fremantle are less likely to receive diabetes education or to perform self-monitoring of blood glucose (33), indicating that access to health care could be important.

The strengths of the present study include the representative nature of the cohort, the detailed nature of the assessment of a large number of important diabetes-related variables, the large sample size including men, and the duration of follow-up. The main limitations were the reliance on self-report for the assessments of disability, mobility, and arthritis and the lack of data on cognitive function. We also have no knowledge of the mode of development of functional limitation in these patients, which can occur transiently, progressively, or in a catastrophic fashion.

Our data extend the results of previous studies of disability in older people with diabetes and provide a conceptual framework that may help to clarify the causal pathways leading to disability (34). For instance, studying the causes of the progression from preclinical to clinical mobility problems in diabetes may be critical in understanding the overall disablement process. In the clinical sphere, it is important to assess patients with type 2 diabetes for early limitations in mobility to consider appropriate preventive activities and avert a decline to physical disability.

Figure 1—

Survival probability curves derived from Kaplan-Meier analysis of percentages of patients remaining free of any difficulty in basic ADLs in two groups of patients defined by baseline mobility status. In each case, censored data points are indicated by +.

Figure 1—

Survival probability curves derived from Kaplan-Meier analysis of percentages of patients remaining free of any difficulty in basic ADLs in two groups of patients defined by baseline mobility status. In each case, censored data points are indicated by +.

Close modal
Table 1—

Baseline variables that were significantly associated either with the subsequent development of mobility impairment or ADL disability and selected nonsignificant variables in patients with type 2 diabetes*

Baseline variablesNormalMobility impairedP valueNormalADL disabledP value
n 585 233  765 169  
Age (years) 60.8 ± 10.2 66.8 ± 9.2 <0.001 62.6 ± 10.3 67.6 ± 9.4 <0.001 
Sex (% men) 50.9 47.6 0.44 49.4 50.9 0.74 
Diabetes duration (years) 3.0 (0.6–6.3) 4.0 (1.4–10.0) <0.001 3.0 (0.8–7.3) 4.0 (1.0–11.0) 0.009 
BMI 29.5 ± 5.5 29.6 ± 5.6 0.79 29.5 ± 5.3 29.6 ± 5.1 0.77 
Therapy (%)       
    Diet 37.8 28.9 0.018 35.1 30.4 0.28 
    OHAs 54.5 55.2 0.88 55.3 54.8 0.93 
    Insulin (± OHAs) 7.7 15.9 0.001 9.6 14.9 0.05 
Systolic blood pressure (mmHg) 147 ± 22 153 ± 23 0.001 149 ± 23 153 ± 23 0.038 
Antihypertensives (%) 41.2 59.7 <0.001 46.0 61.5 <0.001 
ACR (mg/mmol) 2.3 (0.6–8.2) 3.7 (0.8–17.0) <0.001 2.6 (0.7–10.5) 3.8 (0.9–16.6) 0.002 
Neuropathy (%) 25.7 34.8 0.025 25.7 34.8 0.025 
Retinopathy (%) 11.4 19.6 0.003 12.7 20.0 0.019 
Visual acuity (%)       
    Normal 82.9 79.1 0.28 81.7 79.3 0.55 
    Impaired 14.8 17.9 0.36 16.2 15.7 1.00 
    Blindness 2.3 3.4 0.60 2.1 5.0 0.07 
Claudication (%) 8.2 13.7 0.019 9.0 20.7 <0.001 
ABI ≤ 0.9 (%) 22.9 34.4 0.001 26.6 29.7 0.44 
CVD (%) 3.9 15.0 <0.001 5.6 18.9 <0.001 
CHD (%) 22.9 37.9 <0.001 28.0 38.7 0.009 
Ethnic background (%)       
    Anglo-Celt 63.1 66.5 0.38 64.8 60.9 0.38 
    Southern European 18.5 19.3 0.77 16.6 24.3 0.026 
    Other European 8.0 6.0 0.38 8.1 8.3 0.88 
    Asian 4.3 2.6 0.31 3.8 1.8 0.25 
    Mixed/other 5.3 4.7 0.86 5.8 3.6 0.34 
    Indigenous Australian 0.9 0.9 1.00 0.9 1.2 0.67 
Nonfluent in English (%) 13.2 18.5 0.06 12.0 24.9 <0.001 
≥ Secondary education (%) 77.7 72.0 0.09 76.5 67.9 0.023 
Married (%) 73.5 65.7 0.026 68.9 66.9 0.65 
Exercise (%) 80.8 72.5 0.011 79.6 63.1 <0.001 
Smoking status (%):       
    Never 47.0 39.9 0.061 46.7 38.1 0.049 
    Ex-smoker 40.1 44.4 0.27 38.9 47.6 0.046 
    Current 12.9 15.9 0.26 14.3 14.3 1.00 
Alcohol (drinks/day) 0 (0–0.8) 0 (0–0.6) 0.06 0 (0–0.8) 0 (0–1.4) 0.23 
Depression (%) 24.8 30.2 0.13 26.6 37.3 0.006 
Taking antipsychotics (%) 4.8 3.4 0.46 4.6 7.7 0.12 
Arthritis (%) 43.1 64.4 <0.001 49.3 63.9 0.001 
Respiratory disease (%) 9.6 12.9 0.17 10.5 18.3 0.006 
Mobility problems — — — 8.7 33.9 <0.001 
Baseline variablesNormalMobility impairedP valueNormalADL disabledP value
n 585 233  765 169  
Age (years) 60.8 ± 10.2 66.8 ± 9.2 <0.001 62.6 ± 10.3 67.6 ± 9.4 <0.001 
Sex (% men) 50.9 47.6 0.44 49.4 50.9 0.74 
Diabetes duration (years) 3.0 (0.6–6.3) 4.0 (1.4–10.0) <0.001 3.0 (0.8–7.3) 4.0 (1.0–11.0) 0.009 
BMI 29.5 ± 5.5 29.6 ± 5.6 0.79 29.5 ± 5.3 29.6 ± 5.1 0.77 
Therapy (%)       
    Diet 37.8 28.9 0.018 35.1 30.4 0.28 
    OHAs 54.5 55.2 0.88 55.3 54.8 0.93 
    Insulin (± OHAs) 7.7 15.9 0.001 9.6 14.9 0.05 
Systolic blood pressure (mmHg) 147 ± 22 153 ± 23 0.001 149 ± 23 153 ± 23 0.038 
Antihypertensives (%) 41.2 59.7 <0.001 46.0 61.5 <0.001 
ACR (mg/mmol) 2.3 (0.6–8.2) 3.7 (0.8–17.0) <0.001 2.6 (0.7–10.5) 3.8 (0.9–16.6) 0.002 
Neuropathy (%) 25.7 34.8 0.025 25.7 34.8 0.025 
Retinopathy (%) 11.4 19.6 0.003 12.7 20.0 0.019 
Visual acuity (%)       
    Normal 82.9 79.1 0.28 81.7 79.3 0.55 
    Impaired 14.8 17.9 0.36 16.2 15.7 1.00 
    Blindness 2.3 3.4 0.60 2.1 5.0 0.07 
Claudication (%) 8.2 13.7 0.019 9.0 20.7 <0.001 
ABI ≤ 0.9 (%) 22.9 34.4 0.001 26.6 29.7 0.44 
CVD (%) 3.9 15.0 <0.001 5.6 18.9 <0.001 
CHD (%) 22.9 37.9 <0.001 28.0 38.7 0.009 
Ethnic background (%)       
    Anglo-Celt 63.1 66.5 0.38 64.8 60.9 0.38 
    Southern European 18.5 19.3 0.77 16.6 24.3 0.026 
    Other European 8.0 6.0 0.38 8.1 8.3 0.88 
    Asian 4.3 2.6 0.31 3.8 1.8 0.25 
    Mixed/other 5.3 4.7 0.86 5.8 3.6 0.34 
    Indigenous Australian 0.9 0.9 1.00 0.9 1.2 0.67 
Nonfluent in English (%) 13.2 18.5 0.06 12.0 24.9 <0.001 
≥ Secondary education (%) 77.7 72.0 0.09 76.5 67.9 0.023 
Married (%) 73.5 65.7 0.026 68.9 66.9 0.65 
Exercise (%) 80.8 72.5 0.011 79.6 63.1 <0.001 
Smoking status (%):       
    Never 47.0 39.9 0.061 46.7 38.1 0.049 
    Ex-smoker 40.1 44.4 0.27 38.9 47.6 0.046 
    Current 12.9 15.9 0.26 14.3 14.3 1.00 
Alcohol (drinks/day) 0 (0–0.8) 0 (0–0.6) 0.06 0 (0–0.8) 0 (0–1.4) 0.23 
Depression (%) 24.8 30.2 0.13 26.6 37.3 0.006 
Taking antipsychotics (%) 4.8 3.4 0.46 4.6 7.7 0.12 
Arthritis (%) 43.1 64.4 <0.001 49.3 63.9 0.001 
Respiratory disease (%) 9.6 12.9 0.17 10.5 18.3 0.006 
Mobility problems — — — 8.7 33.9 <0.001 

Data are means ± SD or median (interquartile range) unless otherwise indicated. ABI, ankle-to-brachial index; ACR, albumin-to-creatinine ratio; OHA, oral hypoglycemic agent.

*

Assessed variables with significance level P > 0.20 not shown included fasting glucose, A1C, diastolic blood pressure, lipids, lipid-lowering therapy, lower-limb amputation, or mental illness.

Table 2—

Baseline variables that independently predicted time to progression to mobility impairment and ADL difficulty in patients with type 2 diabetes

VariablesMobility
ADL
Hazard ratioP valueHazard ratioP value
Age (years) 1.06 (1.04–1.08) <0.001 1.05 (1.03–1.07) <0.001 
CVD     
    No   
    Yes 2.23 (1.51–3.33) <0.001 1.92 (1.27–2.91) 0.002 
Any exercise     
    No   
    Yes 0.61 (0.45–0.83) 0.002 0.53 (0.38–0.73) <0.001 
Current smoker     
    No    
    Yes 1.64 (1.12–2.40) 0.010   
Ex-smoker     
    No    
    Yes   1.55 (1.13–2.14) 0.007 
Insulin treatment     
    No    
    Yes 2.17 (1.49–3.18) <0.001   
ln(ACR) (mg/mmol)* 1.15 (1.04–1.26) 0.006   
Neuropathy     
    No    
    Yes 1.40 (1.04–1.88) 0.027   
Arthritis     
    No    
    Yes 1.82 (1.37–2.42) <0.001   
Married     
    No    
    Yes 0.68 (0.51–0.92) 0.01   
Claudication     
    No    
    Yes   1.67 (1.13–2.46) 0.010 
Mobility problems     
    No NA   
    Yes   3.22 (2.28–4.57) <0.001 
Depression     
    No    
    Yes   1.41 (1.02–1.95) 0.038 
Nonfluent in English     
    No    
    Yes   2.83 (1.96–4.08) <0.001 
Indigenous Australian     
    No    
    Yes   4.33 (1.04–18.08) 0.044 
VariablesMobility
ADL
Hazard ratioP valueHazard ratioP value
Age (years) 1.06 (1.04–1.08) <0.001 1.05 (1.03–1.07) <0.001 
CVD     
    No   
    Yes 2.23 (1.51–3.33) <0.001 1.92 (1.27–2.91) 0.002 
Any exercise     
    No   
    Yes 0.61 (0.45–0.83) 0.002 0.53 (0.38–0.73) <0.001 
Current smoker     
    No    
    Yes 1.64 (1.12–2.40) 0.010   
Ex-smoker     
    No    
    Yes   1.55 (1.13–2.14) 0.007 
Insulin treatment     
    No    
    Yes 2.17 (1.49–3.18) <0.001   
ln(ACR) (mg/mmol)* 1.15 (1.04–1.26) 0.006   
Neuropathy     
    No    
    Yes 1.40 (1.04–1.88) 0.027   
Arthritis     
    No    
    Yes 1.82 (1.37–2.42) <0.001   
Married     
    No    
    Yes 0.68 (0.51–0.92) 0.01   
Claudication     
    No    
    Yes   1.67 (1.13–2.46) 0.010 
Mobility problems     
    No NA   
    Yes   3.22 (2.28–4.57) <0.001 
Depression     
    No    
    Yes   1.41 (1.02–1.95) 0.038 
Nonfluent in English     
    No    
    Yes   2.83 (1.96–4.08) <0.001 
Indigenous Australian     
    No    
    Yes   4.33 (1.04–18.08) 0.044 

Data are hazard ratio (95% CI). ACR, albumin-to-creatinine ratio; NA, not applicable.

*

A 2.72-fold increase in ACR corresponds to an increase of 1 in ln(ACR).

The FDS was funded by the Raine Foundation, University of Western Australia.

1.
Gregg EW, Beckles GLA, Williamson DF, Leveille SG, Langlois JA: Diabetes and physical disability among older U.S. adults.
Diabetes Care
23
:
1272
–1277,
2000
2.
Volpato S, Blaum C, Resnick H, Ferrucci L, Fried LP, Guralnick JM: Comorbidities and impairments explaining the association between diabetes and lower-limb disability.
Diabetes Care
25
:
678
–683,
2002
3.
Maggi S, Noale M, Gallina C, Marzari C, Bianchi D, Limongi F, Crepaldi G: Physical disability among older Italians with diabetes: the ILSA study.
Diabetologia
47
:
1957
–1962,
2004
4.
Seeman TE, Charpentier PA, Berkman LF, Tinetti ME, Guralnik JM, Albert M, Blazer D, Rowe JW: Predicting changes in physical performance in a high-functioning elderly cohort: MacArthur studies of successful aging.
J Gerontol
49
:
M97
–M108,
1994
5.
Gregg EW, Mangione CM, Cauley JA, Thompson TJ, Schwartz AV, Ensrud KE, Nevitt MC: Diabetes and incidence of functional disability in older women.
Diabetes Care
25
:
61
–67,
2002
6.
Volpato S, Ferrucci L, Blaum C, Ostir G, Cappola A, Fried LP, Fellin R, Guralnik JM: Progression of lower-extremity disability in older women with diabetes: the Women’s Health and Aging Study.
Diabetes Care
26
:
70
–75,
2002
7.
Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS: Diabetes trends in the US: 1990–1998.
Diabetes Care
23
:
1278
–1283,
2000
8.
Fried LP, Kronmal RA, Newman AB, Bild DE, Mittelmark MB, Polak JF, Robbins JA, Gardin JM: Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study.
JAMA
279
:
585
–592,
1998
9.
Anderson G, Knickman J: Changing the chronic care system to meet people’s needs.
Health Affairs
20
:
146
–160,
2001
10.
Wagner EH, LaCroix AZ, Grothaus L, Leveille SG, Hecht JA, Artz K, Odle K, Buchner DM: Preventing disability and falls in older adults: a population-based randomised trial.
Am J Publ Health
84
:
1800
–1806,
1994
11.
Verbrugge LM, Jette AM: The disablement process.
Soc Sci Med
38
:
1
–14,
1994
12.
Stuck AE, Walthert JM, Nikolaus T, Bula CJ, Hohmann C, Beck JC: Risk factors for functional status decline in community-living elderly people: a systematic literature review.
Soc Sci Med
48
:
445
–469,
1999
13.
Fried LM, Guralnik JM: Disability in older adults: evidence regarding significance, etiology, and risk.
J Am Geriatr Soc
45
:
92
–100,
1997
14.
Guralnick JM, Ferrucci L, Simonsick EM, Salive ME, Wallace RB: Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability.
N Engl J Med
332
:
556
–561,
1995
15.
Gill TM, Williams CS, Tinetti ME: Assessing risk for the onset of functional dependence among older adults: the role of physical performance.
J Am Geriatr Soc
43
:
603
–609,
1995
16.
Bruce DG, Davis WA, Davis TME: Glycemic control in older diabetic patients in the Fremantle Diabetes Study.
J Am Geriatr Soc
48
:
1449
–1453,
2000
17.
Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR: Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study.
Diabet Med
17
:
667
–674,
2000
18.
Davis TME, Davis W, Mulder JW, Fortune P, Bruce DG: Silent myocardial infarction and its prognosis in a community-based cohort of diabetic patients: the Fremantle Diabetes Study.
Diabetologia
47
:
395
–399,
2004
19.
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA: A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy.
Diabetes Care
17
:
1281
–1289,
1994
20.
Gillett M, Davis WA, Bruce DG, Davis TME: Prospective evaluation of carotid bruit as a predictor of first stroke in type 2 diabetes: the Fremantle Diabetes Study.
Stroke
34
:
2145
–2151,
2003
21.
Gudex C, Kind P.
The QALY Toolkit
. York, U.K., University of York,
1986
.
22.
Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G: The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview.
J Clin Psychiatry
59 (Suppl. 20)
:
22
–33,
1998
23.
Gill TM, Robison JT, Tinetti ME: Difficulty and dependence: two components of the disability continuum among community-living older persons.
Ann Intern Med
128
:
96
–101,
1998
24.
Therneau TM, Grambsch PM. Testing proportional hazards. In
Modeling Survival Data: Extending the Cox Model
. Berlin, Springer-Verlag, 2000
25.
Cavanagh PR, Derr JA, Ulbrecht JS, Maser RE, Orchard TJ: Problems with gait and posture in neuropathic patients with insulin-dependent diabetes.
Diabet Med
9
:
469
–474,
1992
26.
Resnick HE, Stansberry KB, Harris TB, Tirrivedi M, Smith K, Morgan P, Vinik AI: Diabetes, peripheral neuropathy, and old age disability.
Muscle Nerve
25
:
43
–50,
2002
27.
McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, Pearce WH, Schneider JR, Ferrucci L, Celic L, Taylor LM, Vonesh E, Martin GJ, Clark E: Functional decline in peripheral arterial disease: associations with the ankle:brachial index and leg symptoms.
JAMA
292
:
453
–461,
2004
28.
Anderson RJ, Freedland KE: Clouse RE. Lustman PJ: The prevalence of comorbid depression in adults with diabetes: a meta-analysis.
Diabetes Care
24
:
1069
–1078,
2001
29.
Kriegsman DM, Deeg DJ: Stalman WA: Comorbidity of somatic chronic diseases and decline in physical functioning: the Longitudinal Aging Study Amsterdam.
J Clin Epidemiol
57
:
55
–65,
2004
30.
Evans WJ: What is sarcopenia?
J Gerontol A Biol Sci Med Sci
50 (Spec no.):5–8, 1995
31.
Bergstrom J Lindholm B: Malnutrition, cardiac disease, and mortality: an integrated point of view.
Am J Kidney Dis
32
:
834
–840,
1998
32.
Bruce DG, Baird M, Saddler AH, Goldswain P: A preliminary survey of patients seen by the Kimberley Aged Care Assessment Team.
Australas J Ageing
17
:
95
–97,
1998
33.
Bruce DG, Davis WA, Cull CA, Davis TME: Diabetes education and knowledge in patients with type 2 diabetes from the community: the Fremantle Diabetes Study.
J Diabetes Complications
17
:
82
–89,
2003
34.
Fried LP, Herdman SJ, Kuhn KE, Rubin G, Turano K: Preclinical disability: hypothesis about the bottom of the iceberg.
J Aging Health
3
:
285
–300,
1991

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.